Acid-inhibitory effects of omeprazole and lansoprazole inHelicobacter pylori-negative healthy subjects-Reference-Cited by-同舟云学术

Acid-inhibitory effects of omeprazole and lansoprazole inHelicobacter pylori-negative healthy subjects

Published:1998-04 Issue:4 Volume:12 Page:329-335
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

Geus ,Mulder ,Nicolai ,Boomgaard D. M. Van Den,Lamers

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2036.1998.00304.x/fullpdf

Reference23 articles.

1. The mechanism of action of the gastric acid secretion inhibitor omeprazole;Lindberg;J Med Chem,1986

2. Possible mechanism for the inhibition of acid formation by the proton pump inhibitor AG-1749 in isolated canine parietal cells;Nagaya;J Pharmacol Exp Ther,1990

3. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial;Hatlebakk;Scand J Gastroenterol,1993

4. Lansoprazole versus omeprazole in active duodenal ulcer. A double-blind, randomized, comparative study;Ekström;Scand J Gastroenterol,1995

5. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome;Hirschowitz;Aliment Pharmacol Ther,1996

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The views of African and Middle Eastern Gastroenterologists on the management of mild-to-moderate, non-erosive gastro-esophageal reflux disease (GERD);Expert Review of Gastroenterology & Hepatology;2022-02-25

2. Effect of Lansoprazole on the Control of the Intragastric pH in a Patient with Short Bowel Syndrome;Internal Medicine;2019-06-15

3. Interchangeable Use of Proton Pump Inhibitors Based on Relative Potency;Clinical Gastroenterology and Hepatology;2018-06

4. Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors;Journal of Neurogastroenterology and Motility;2013-01-31

5. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism;Alimentary Pharmacology & Therapeutics;2012-02-13